Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a myeloproliferative bone marrow neoplasm that occurs because of a fusion gene called BCR-ABL1. Imatinib -the inhibitor of this fusion geneis the target therapy in CML. But unfortunately, resistance against imatinib occurs in some patients. In September 2019 47-year...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2024-03-01
|
| Series: | Caucasian Medical Journal |
| Subjects: | |
| Online Access: | https://caucasianmedj.com/articles/imatinib-resistance-without-bcrabl-point-mutation-in-chronic-myeloid-leukemia/doi/cmj.galenos.2024.36855 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594033001627648 |
|---|---|
| author | Aytan Shirinova |
| author_facet | Aytan Shirinova |
| author_sort | Aytan Shirinova |
| collection | DOAJ |
| description | Chronic myeloid leukemia (CML) is a myeloproliferative bone marrow neoplasm that occurs because of a fusion gene called BCR-ABL1. Imatinib -the inhibitor of this fusion geneis the target therapy in CML. But unfortunately, resistance against imatinib occurs in some patients. In September 2019 47-year-old male was diagnosed with CML-chronic phase and intermediate risk group. Imatinib has been prescribed as a first-line treatment. The patient did not achieve a major molecular response (MMR). Next-generation sequencing using a 54 myeloid-targeted gene panel was negative for ABL1 L248V, G250E, Y253H, E255K, F311L, T315I, F317L, F311I, M351T, and other point mutations. After Nilotinib patient achieved MMR within two years. Imatinib resistance is impediment during treating CML. In the future, new molecules for BCR-ABL inhibitors, combination therapy, and molecules entering the blood-brain barrier may improve the outcomes of therapy and prevent imatinib resistance in CML. |
| format | Article |
| id | doaj-art-d19cd61d5c704ceb82f2a3b96da3241e |
| institution | Kabale University |
| issn | 2980-1818 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Caucasian Medical Journal |
| spelling | doaj-art-d19cd61d5c704ceb82f2a3b96da3241e2025-01-20T07:10:01ZengGalenos Publishing HouseCaucasian Medical Journal2980-18182024-03-01211210.4274/cmj.galenos.2024.36855Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid LeukemiaAytan Shirinova0https://orcid.org/0000-0002-2525-3069National Hematology and Blood Transfusion Center, Department of Hematology, Baku, AzerbaijanChronic myeloid leukemia (CML) is a myeloproliferative bone marrow neoplasm that occurs because of a fusion gene called BCR-ABL1. Imatinib -the inhibitor of this fusion geneis the target therapy in CML. But unfortunately, resistance against imatinib occurs in some patients. In September 2019 47-year-old male was diagnosed with CML-chronic phase and intermediate risk group. Imatinib has been prescribed as a first-line treatment. The patient did not achieve a major molecular response (MMR). Next-generation sequencing using a 54 myeloid-targeted gene panel was negative for ABL1 L248V, G250E, Y253H, E255K, F311L, T315I, F317L, F311I, M351T, and other point mutations. After Nilotinib patient achieved MMR within two years. Imatinib resistance is impediment during treating CML. In the future, new molecules for BCR-ABL inhibitors, combination therapy, and molecules entering the blood-brain barrier may improve the outcomes of therapy and prevent imatinib resistance in CML.https://caucasianmedj.com/articles/imatinib-resistance-without-bcrabl-point-mutation-in-chronic-myeloid-leukemia/doi/cmj.galenos.2024.36855imatinib-resistancecmlabl1 domain mutations |
| spellingShingle | Aytan Shirinova Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia Caucasian Medical Journal imatinib-resistance cml abl1 domain mutations |
| title | Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia |
| title_full | Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia |
| title_fullStr | Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia |
| title_full_unstemmed | Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia |
| title_short | Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia |
| title_sort | imatinib resistance without bcr abl point mutation in chronic myeloid leukemia |
| topic | imatinib-resistance cml abl1 domain mutations |
| url | https://caucasianmedj.com/articles/imatinib-resistance-without-bcrabl-point-mutation-in-chronic-myeloid-leukemia/doi/cmj.galenos.2024.36855 |
| work_keys_str_mv | AT aytanshirinova imatinibresistancewithoutbcrablpointmutationinchronicmyeloidleukemia |